This is in line with other studies, showing that the functional outcome improvement is related to the amount of Aβ and p-Tau in the brain of 3xTg-AD [27], and that the curtailment of both the central and the peripheral immune response is followed by improvement of brain tissue parameters, along with decreased inflammatory markers and reduced amounts of anomalous proteins in discrete brain areas [28]. The gene discussed is MAPT; the disease is Alzheimer disease.